Collegium Pharmaceutical (COLL) Expected to Announce Quarterly Earnings on Thursday

Collegium Pharmaceutical (NASDAQ:COLL) will likely be announcing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Collegium Pharmaceutical to post earnings of $1.86 per share and revenue of $216.03 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The company had revenue of $199.88 million for the quarter, compared to analysts’ expectations of $199.62 million. During the same quarter in the previous year, the business posted $1.68 EPS. Collegium Pharmaceutical’s revenue was up 6.3% compared to the same quarter last year. On average, analysts expect Collegium Pharmaceutical to post $6.42 EPS for the current fiscal year and $5.89 EPS for the next fiscal year.

Collegium Pharmaceutical Trading Up 1.0%

NASDAQ:COLL opened at $23.23 on Thursday. The stock has a market cap of $756.37 million, a price-to-earnings ratio of 18.73, a PEG ratio of 0.71 and a beta of 0.73. The company has a quick ratio of 0.84, a current ratio of 1.03 and a debt-to-equity ratio of 3.32. The company’s 50 day moving average price is $23.47 and its 200-day moving average price is $33.59. Collegium Pharmaceutical has a 52 week low of $21.43 and a 52 week high of $50.79.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on COLL shares. Wall Street Zen cut shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Oppenheimer started coverage on shares of Collegium Pharmaceutical in a research report on Wednesday, September 23rd. They set an “outperform” rating and a $50.00 target price for the company. Piper Sandler reaffirmed a “neutral” rating and set a $43.00 target price (down from $45.00) on shares of Collegium Pharmaceutical in a report on Friday, August 7th. Needham & Company LLC decreased their price target on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Finally, Truist Financial assumed coverage on shares of Collegium Pharmaceutical in a research report on Wednesday, September 9th. They issued a “buy” rating and a $49.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $48.71.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and central nervous system disorders. The company primarily serves the U.S. market and emphasizes products designed to address significant patient and healthcare-provider needs.

Its pain portfolio includes Xtampza ER, an extended-release oxycodone formulation designed with abuse-deterrent properties, as well as Nucynta and Nucynta ER, which contain tapentadol and are used to treat acute and chronic pain.